NASDAQ:ABVC
Abvc Biopharma, Inc.
Abvc Biopharma, Inc.'s revenue fell 41.9% in fiscal 2025 to $296,000 while operating margin fell to −2416.0%. The diluted share count rose 72.3%.Summary generated from Abvc Biopharma, Inc.'s SEC filings. Latest annual report filed Mar 3, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$296,000
Revenue growth−41.9%
Revenue, 5-yr CAGR−9.3%
Gross marginn/a
Operating margin−2416.0%
Net margin−2671.8%
ROIC−86.9%
Return on equity−128.2%
Debt / equity0.07
Free cash flown/a
FCF marginn/a
Share count change+72.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 1 | 0 | 1 | 0 |
| Operating income | −12 | −15 | −7 | −5 | −7 |
| Net income | −13 | −16 | −8 | −5 | −8 |
| Free cash flow | −8 | −8 | −4 | n/a | n/a |
Recent filings
- DEF 14AProxy statement
Sep 29, 2026 - 8-KEntry into a material agreement
Aug 27, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-K/AAmended other events
Aug 12, 2026 - 8-KOther events
Aug 4, 2026 - 8-KChange in auditor
Jul 2, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 18, 2026 - 8-KResults of a shareholder vote
Mar 27, 2026